Synonym
OGT-719; OGT719; OGT 719
IUPAC/Chemical Name
5-Fluoro-1-beta-D-galactopyranosyl-2,4(1H,3H)-pyrimidinedione
InChi Key
YHWGRVDTEORPPJ-WENHOLORSA-N
InChi Code
InChI=1S/C10H13FN2O7/c11-3-1-13(10(19)12-8(3)18)9-7(17)6(16)5(15)4(2-14)20-9/h1,4-7,9,14-17H,2H2,(H,12,18,19)/t4-,5+,6+,7-,9-/m1/s1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
292.22
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Desmoulin F, Gilard V, Malet-Martino M, Martino R, Molina C, Smith P. Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats, in tumour models and in patients. Xenobiotica. 2003 Mar;33(3):289-303. doi: 10.1080/0049825021000048818. PMID: 12637246.
2: Rohlff C, Watson SA, Morris TM, Skelton L, Jackman AL, Page MJ. A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. Cancer Res. 1999 Mar 15;59(6):1268-72. PMID: 10096558.
3: Mok TS, Leung TW, Brown G, Moyses C, Chan AT, Yeo W, Wong H, Chak K, Johnson P. A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. Acta Oncol. 2004;43(3):245-51. doi: 10.1080/02841860310023525. PMID: 15244247.
4: Sharma RA, Eatock MM, Twelves CJ, Brown G, McLelland HR, Clayton KT, O'Byrne KJ, Moyses C, Carmichael J, Steward WP. Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemother Pharmacol. 2001 Sep;48(3):197-201. doi: 10.1007/s002800100332. PMID: 11592340.
